Jeroen J. Bax1, MD, PhD; Victoria Delgado1, MD, PhD
1. Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
Transcatheter aortic valve implantation (TAVI) has become an accepted alternative to surgical aortic valve replacement (SAVR). TAVI has been carefully evaluated in head-to-head comparisons in the PARTNER studies, with the most recent PARTNER 3 study (1,000 patients) showing that TAVI was superior to SAVR in preventing death, stroke and repeat hospitalisation at one-year follow-up1. Similarly, the EVOLUT Low Risk trial (1,403 patients) showed no difference in two-year outcomes (mortality, stroke) between SAVR and TAVI2. More importantly, in both trials, the one-year/two-year event rates were extremely low.
In addition to these “traditional events”, other events include development of valve ...